|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103 GBX | 0.00% |
|
-0.48% | +18.39% |
| Apr. 02 | Roadside shares suspended; Adnams looks for funds | AN |
| Mar. 21 | Diaceutics upgrades diagnositc commercialisation platform, DXRX | AN |
Diaceutics PLC reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was GBP 9.92 million compared to GBP 7.53 million a year ago. Net loss was GBP 1.49 million compared to GBP 0.767 million a year ago.
Basic loss per share from continuing operations was GBP 0.0176 compared to GBP 0.0091 a year ago. Diluted loss per share from continuing operations was GBP 0.0176 compared to GBP 0.0091 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +18.39% | 109M | |
| +5.73% | 4.05B | |
| +23.61% | 1.94B | |
| -36.44% | 1.97B | |
| -1.59% | 1.74B | |
| -15.36% | 1.61B | |
| -24.26% | 1.36B | |
| -5.20% | 1.2B | |
| -6.85% | 1.02B | |
| +119.33% | 694M |
DIACEUTICS PLC 
